PDCD1 and hepatocellular carcinoma: However, anti-PD-1/PD-L1 monotherapy is ineffective for nearly 80% of HCC patients, so the frequency of response to anti-PD-1/PD-L1 therapies is still unsatisfactory and better knowledge of the tolerance mechanisms of such therapies is urgently needed [97, 98].